A treatment and withdrawal trial of besipirdine in Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 10, Issue 2, 1996, Pages 93-102

  Huff, F J ^a,k,l   Antuono, P G ^b   Delagandara, J E ^c   McDonald, M A ^d   Cutler, N R ^e   Cohen, S R ^f   Green, R C ^g   Zemlan, F P ^h   Crismon, M L ⁱ   Alter, M ^j   Shipley, J E ^k   Reichman, W E ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c North Broward Medical Center   (United States)

^d Alzheimer's Diagnostic Clinic   (United States)

^e CALIFORNIA CLINICAL TRIALS   (United States)

^f Suncoast Medical Clinic   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ Austin Diagnostic Clinic   (United States)

^j DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^k SANOFI   (France)

^l University of Medicine and Dentistry   (United States)

more..

Author keywords

Adrenergic; Besipirdine; Cholinergic; Pharmacology; Treatment withdrawal

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT;

ADRENERGIC TRANSMISSION; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; VERTIGO;

AGED; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; PARASYMPATHOLYTICS; PYRIDINES; TIME FACTORS;

EID: 9344219884     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199601020-00007     Document Type: Article

References (42)

1. Adolfsson, R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer's type. Br J Psychiatr 1979;135:216-23.
2. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-84.
3. Antuono P. Efficacy and safety of velnacrine for Alzheimer's disease: a double-blind, placebo-controlled study. Arch Intern Med 1995;155:1766-72.
4. Arai H, Kosaka K, Iizuka R. Changes of biogenic amines and their metabolites in post-mortem brains from patients with Alzheimer's-type dementia. J Neurochem 1984;43:388-93.
5. Arnsten AFT, Goldman-Rakic PS, α2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230:1273-6.
6. Bierer LM, Aisen PS, Davidson, et al. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:98-104.
7. Bleeker ML, Bolla-Wilson K, Kawas C, Agnew J. Age-specific norms for the Mini-Mental State Exam. Neurology 1988;38:1565-8.
8. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
9. Bondareff W, Montjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982;32:164-8.
10. Cornfeldt M, Wirtz-Brugger F, Szewczak M, et al. HP 749: a pharmacological profile of a therapeutic agent for Alzheimer's disease (I). Abstr Soc Neurosci 1990;16:612.
11. Davidson M, Zemishlany Z, Mohs RC, et al. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 1988;23:485-90.
12. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
13. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind placebo controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
14. Drukarch B, Kits KS, Van der Meer EG, Lodder JC, Stoof JC. 9-Amino-1,2,3,4-tetrahydeoacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase and slow outward K+ current. Eur J Pharmacol 1987;14:153-7.
15. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
16. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method of grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-98.
17. Hubbard JW, Hsu RS, Griffiths L, Dean R, Dileo EM, Hintze TH. The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine hydrochloride) and metabolite P86-7480 in the conscious monkey. J Clin Pharmacol 1991;3:864.
18. Huff FJ. Multiple neurotransmitter strategies for treatment of Alzheimer's disease. In: Cutler NR, Gottfries CG, Siegfried K, eds. Alzheimer's disease: clinical and treatment perspectives. Chichester, England: John Wiley & Sons, 1995:151-62.
19. Huff FJ, Antuono P, Murphy M, Beyer J, Dobson C. Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann NY Acad Sci 1991;640:263-7.
20. Huger F, Smith C, Petko WW, Conway PG, Effland R, Klein J. HP 749, a potential agent for the treatment of Alzheimer's disease (II): neurochemical profile. Abstr Soc Neurosci 1990;16:612.
21. Kinney JM, Stephen MAP. Hassles and uplifts of giving care to a family member with dementia. Psychol Aging 1989;4:402-8.
22. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
23. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The clinician interview-based impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
24. Lavretsky EP, Jarvik LE A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzheimer's disease? A review. J Clin Psychopharmacol 1992;12:110-8.
25. Mann DMA, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982;45:113-9.
26. McKhann G, Drachman D, Folstein M, Katzman R, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-44.
27. Mohr E, Schlegel J, Fabbrini G, et al. Clonidine treatment of Alzheimer's disease. Arch Neurol 1989;46:376-8.
28. Moore MJ, Clipp EC. Alzheimer's disease and caregiver time. Lancet 1994;343:239-40.
29. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-7.
30. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9.
31. Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci 1981;51:279-87.
32. Reisberg B, Ferris SH, de Leo MJ, Crook T. The Global Deterioration Scale for assessment of primary dementia. Am J Psychiatry 1982;139:1136-9.
33. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
34. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1979;7:486-8.
35. Rossor M, Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull 1986;42:70-4.
36. Santucci AC, Haroutunian V, Davis KL. Pharmacological alleviation of combined cholinergic/noradrenergic lesion induced memory deficits in rats. Clin Neuropharmacol 1991;14:S1-8.
37. Shutske GM, Pierrat FA, Kapples KJ, et al. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as a potential Alzheimer's disease therapeutic. J Med Chem 1989;32:1805-13.
38. Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR. A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci 1995;57:1241-8.
39. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-6.
40. Terry RD, Katzman R. Senile dementia of the Alzheimer type. Ann Neurol 1983;14:497-506.
41. Wesseling H, Agoston S, Van Dam GB, Pasma J, DeWitt DT, Havinga H. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease. N Engl J Med 1984;10:988-9.
42. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.